ENTRY       D10071                      Drug
NAME        Ixekizumab (USAN);
            Ixekizumab (genetical recombination) (JAN);
            Taltz (TN)
PRODUCT     TALTZ (Eli Lilly and Company)
SEQUENCE    (A chain)
            QVQLVQSGAE VKKPGSSVKV SCKASGYSFT DYHIHWVRQA PGQGLEWMGV INPMYGTTDY
            NQRFKGRVTI TADESTSTAY MELSSLRSED TAVYYCARYD YFTGTGVYWG QGTLVTVSSA
            STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTKTY TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
            VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN
            QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN
            VFSCSVMHEA LHNHYTQKSL SLSLG
            (B chain)
            DIVMTQTPLS LSVTPGQPAS ISCRSSRSLV HSRGNTYLHW YLQKPGQSPQ LLIYKVSNRF
            IGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHLP FTFGQGTKLE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: A22-A96, A133-B219, A146-A202, A225-A'225, A228-A'228, A260-A320, A366-A424, A'22-A'96, A'133-B'219, A'146-A'202, A'260-A'320, A'366-A'424, B23-B'93, B139-B199, B'23-B'93, B'139-B'199)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC13
            Product: D10071<JP/US>
EFFICACY    Antipsoriatic, Anti-IL-17A antibody
  DISEASE   Plaque psoriasis [DS:H01656]
            Psoriatic arthritis [DS:H01656]
  TYPE      Monoclonal antibody
COMMENT     Treatment of autoimmune diseases
TARGET      IL17A [HSA:3605] [KO:K05489]
  PATHWAY   hsa04060(3605)  Cytokine-cytokine receptor interaction
            hsa04657(3605)  IL-17 signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC13 Ixekizumab
                  D10071  Ixekizumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Ixekizumab
                 D10071  Ixekizumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D10071  Ixekizumab (USAN); Ixekizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10071  Ixekizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10071  Ixekizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL17A
                 D10071  Ixekizumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10071
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10071
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10071
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10071
DBLINKS     CAS: 1143503-69-8
            PubChem: 135626791
///
